What to Watch at ASCO 2026: A Thoracic Oncologist’s Guide to the Lung Cancer Program

Dan Morgenstern, MD University of Miami Sylvester Comprehensive Cancer Center | Chinmay Jani, MD University of Miami Health System | Gilberto Lopes, MD Sylvester Comprehensive Cancer Center, University of Miami

Key Points

• LIBRETTO-432 tested adjuvant selpercatinib in RET fusion–positive non–small cell lung cancer (NSCLC), while HARMONi-6 evaluated whether the PD-1/VEGF bispecific ivonescimab improves survival over standard chemoimmunotherapy in first-line squamous disease.

• Molecular profiling now guides most NSCLC treatment decisions, and prior successes with adjuvant EGFR and ALK inhibitors set the stage for expanding targeted therapy into earlier-stage, resected disease.

• Emerging combinations show promise in lung cancer but introduce important toxicity considerations.

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting takes place in Chicago, Illinois, May 29 to June 2, with a thoracic oncology program that spans the full spectrum of lung cancer. Two lung cancer trials earned a place in the Plenary Session: LIBRETTO-432, reporting primary event-free survival (EFS) results for adjuvant selpercatinib in resected RET fusion-positive non–small cell lung cancer (NSCLC), and HARMONi-6, presenting overall survival (OS) data from a randomized comparison of ivonescimab plus chemotherapy against a PD-1 inhibitor plus chemotherapy in first-line squamous NSCLC. Results of several non-late-breaking abstracts were released ahead of the meeting and are discussed below; late-breaking abstracts remain under embargo until the day of presentation.

Setting the Stage

Two structural developments provide context for this year’s data. First, NSCLC is now understood as a collection of molecularly distinct subtypes, each with its own treatment logic. Comprehensive genomic profiling identifies actionable driver alterations in the majority of adenocarcinomas: EGFR mutations (approximately 15% in Western patients), ALK rearrangements (5%), RET fusions (2%), KRAS G12C (13%), and rarer targets including MET exon 14 skipping, ROS1, NTRK, BRAF V600E, HER2, and NRG1 fusions. Squamous cell carcinoma, which constitutes roughly 30% of NSCLC, has fewer targetable drivers and has been treated primarily with pembrolizumab-based chemoimmunotherapy since the KEYNOTE-407 results.

Second, adjuvant targeted therapy has become a standard of care following surgery. ADAURA established that adjuvant osimertinib reduces the risk of recurrence or death by 83% in resected EGFR-mutated NSCLC (hazard ratio [HR], 0.17). ALINA demonstrated a 76% reduction in recurrence with adjuvant alectinib in resected ALK-positive disease (HR, 0.24). These results established the rationale for the adjuvant approach now being evaluated in RET fusion-positive NSCLC.

LIBRETTO-432: Adjuvant Selpercatinib in Resected RET Fusion-Positive NSCLC

RET fusions occur in approximately 1% to 2% of NSCLCs and function as oncogenic drivers. The fusion event produces a constitutively active kinase that renders tumor cells dependent on RET signaling regardless of disease stage. Selpercatinib is a selective, central nervous system (CNS)-penetrant RET inhibitor with established activity in the metastatic setting. In the LIBRETTO-001 registrational trial, the objective response rate (ORR) was 83% in treatment-naive patients with RET fusion-positive NSCLC. In LIBRETTO-431, the phase 3 first-line trial, selpercatinib more than doubled progression-free survival (PFS) versus platinum-based chemotherapy with or without pembrolizumab (HR, 0.46).

LIBRETTO-432 enrolled 151 patients with stage Ib to IIIa RET fusion-positive NSCLC following curative-intent surgery, randomizing patients 1:1 to selpercatinib 160 mg twice daily or placebo, with OS as a key secondary end point. In February 2026, the trial sponsor issued a press release, ahead of full data disclosure, reporting a statistically significant EFS improvement; the effect size was characterized as consistent with the adjuvant EGFR and ALK datasets, suggesting an HR in the range of ADAURA (0.17) and ALINA (0.24). The Kaplan-Meier curves, subgroup analyses, and actual HR will be presented for the first time at the Sunday plenary. If confirmed, LIBRETTO-432 would extend the adjuvant targeted therapy paradigm to RET fusion-positive NSCLC and strengthen the case for routine molecular profiling at the time of surgical resection.

HARMONi-6: Ivonescimab vs Tislelizumab Plus Chemotherapy in First-Line Squamous NSCLC

Ivonescimab is a bispecific antibody that simultaneously targets PD-1 and VEGF within a single molecule. Its tetravalent structure creates cooperative binding: the presence of VEGF increases the molecule’s affinity for PD-1 by more than 10-fold. Because VEGF both promotes angiogenesis and suppresses T-cell activity in the tumor microenvironment, combined blockade within a single molecule may offer advantages over sequential or additive combination strategies. A practical distinction from bevacizumab is ivonescimab’s Fc-silenced design, which reduces Fc gammaR-mediated effector function and the associated hemorrhagic risk that has historically precluded anti-VEGF therapy in squamous histology.

HARMONi-6 enrolled 532 patients with previously untreated stage IIIb to IV squamous NSCLC, randomizing to ivonescimab plus carboplatin/paclitaxel or tislelizumab plus the same chemotherapy backbone. PFS results presented at the 2025 European Society for Medical Oncology Congress showed a median PFS of 11.1 versus 6.9 months (HR, 0.60; P <  .0001), with consistent benefit across PD-L1 expression subgroups, including PD-L1–negative patients. The ASCO plenary will present OS, which is the primary question: PFS improvements in advanced NSCLC do not reliably predict survival benefit. The trial was conducted entirely in China, and the global HARMONi-3 trial enrolling patients in the United States and Europe is expected to report PFS data in the second half of 2026.

ALCHEMIST (EA5142): Adjuvant Nivolumab in Resected NSCLC

ALCHEMIST EA5142, the largest US cooperative group trial of adjuvant immunotherapy in NSCLC, reported a negative result. Among 935 patients with resected stage Ib to IIIa, EGFR- and ALK-wild-type NSCLC randomized after surgery and standard adjuvant chemotherapy to nivolumab or observation, adjuvant nivolumab did not improve disease-free survival (DFS) in the intention-to-treat population (median DFS, 71.3 vs 68.8 months; HR, 0.97; 95% CI, 0.8-1.17; P = .78). The PD-L1–high subset (tumor proportion score [TPS] at least 50%) also showed no benefit (HR, 0.86; 95% CI, 0.59 to 1.25). Results were consistent across all prespecified subgroups and sensitivity analyses. Because DFS, the primary end point, was not met, OS testing was prespecified as hierarchical and was not formally evaluated. Median follow-up was 72.6 months.

The contrast between these results and the positive OS data from CheckMate 816, where neoadjuvant nivolumab plus chemotherapy reduced the risk of death by 28% (HR, 0.72), has a plausible biological interpretation: immune checkpoint blockade may be more effective when tumor antigen is present to stimulate T-cell priming. Administering immunotherapy before surgery, in the presence of an intact tumor, appears to generate durable immune responses that post-surgical adjuvant immunotherapy, given to a tumor-free patient months after chemotherapy completion, does not replicate. ALCHEMIST does not address neoadjuvant or perioperative strategies, and the field has moved substantially in that direction since the trial was designed. However, these results provide the most mature and definitive data on post-surgical adjuvant immunotherapy in unselected EGFR/ALK-wild-type NSCLC.

REVOL858R: Erlotinib Plus Ramucirumab vs Osimertinib in First-Line EGFR L858R NSCLC

REVOL858R is a Japanese cooperative group trial addressing an observation from the FLAURA OS analysis: the OS benefit of osimertinib over first-generation EGFR inhibitors was concentrated in patients with exon 19 deletions. In L858R-mutated NSCLC, the OS HR was 0.96. REVOL858R tests a sequencing strategy specific to this subgroup, using erlotinib plus ramucirumab (which showed a PFS HR of 0.59 in RELAY) as initial therapy, followed by osimertinib at T790M-positive progression, versus upfront osimertinib. The primary end point is time to failure of strategy, a composite measure intended to capture total therapeutic benefit across the full treatment sequence. Full results are embargoed.

CROWN at Seven Years: Redefining Long-Term Outcomes in ALK-Positive NSCLC

At 7 years of follow-up, the CROWN trial continues to show results with few precedents in advanced solid tumors. After a median follow-up of 83 months, the median PFS with lorlatinib has not been reached; the 7-year PFS rate is 55% versus 3% with crizotinib (HR, 0.19; 95% CI, 0.13-0.26). Patients who were progression-free at 24 months had a 79% probability of remaining progression-free at year 7, and no new intracranial progression events occurred after month 30, with a median time to IC progression never reached in the lorlatinib arm (HR, 0.06 vs crizotinib). The number of events required for a protocol-specified OS analysis has not yet been met, meaning OS data remain formally immature. Safety data showed no new permanent treatment discontinuations after month 26, and long-term efficacy was similar in patients who required dose reductions and those who did not, a finding relevant to dose management decisions in clinical practice.

TRITON: Dual Checkpoint Inhibition in STK11/KEAP1-Mutant NSCLC

The TRITON interim analysis presents early activity data from a prospective, US-based phase 2b trial testing whether the addition of anti-CTLA-4 therapy to first-line chemoimmunotherapy improves outcomes in STK11, KEAP1, and/or KRAS-mutated non-squamous metastatic NSCLC. At a data cutoff of November 2025, 84 patients had been randomized. The ORR was 39% (95% CI, 24.1-54) with tremelimumab plus durvalumab plus chemotherapy versus 34.9% (95% CI, 20.6-49.1) with pembrolizumab plus chemotherapy; confidence intervals overlapped substantially. Response durability was more differentiated: 100% of responders in the tremelimumab arm remained in response at 6 months versus 58.3% in the pembrolizumab arm, with median duration of response not reached versus 6.4 months. Grade 3/4 adverse events (AEs) were similar between arms (41.5% vs 41.9%).

What TRITON presents at this meeting is activity data: ORR and duration of response. Its primary end point of PFS and co-primary end point of OS in the STK11/KEAP1 subset remain too immature to evaluate, and the question this trial was designed to answer is still unanswered. Median safety follow-up was 5.6 months and PFS data were blinded to the sponsor at this interim. The response durability signal is directionally consistent with the hypothesis that CTLA-4 blockade deepens immune activation in this immunosuppressed tumor subtype, and the safety profile is acceptable, but the definitive read of this trial awaits its primary end points.

OptiTROP-Lung05: Sacituzumab Tirumotecan Plus Pembrolizumab in First-Line PD-L1–Positive NSCLC

OptiTROP-Lung05 is the first phase 3 trial to demonstrate a significant PFS benefit for an antibody-drug conjugate (ADC) plus PD-1 inhibitor combination over pembrolizumab alone in first-line NSCLC. Among 413 patients with treatment-naive, PD-L1–positive (TPS at least 1%), EGFR/ALK-negative advanced NSCLC, sacituzumab tirumotecan plus pembrolizumab reduced the risk of progression or death by 65% compared with pembrolizumab alone (HR, 0.35; 95% CI, 0.26-0.47; P < .0001), with median PFS not reached versus 5.7 months. The ORR was 70.2% versus 42%. PFS benefit was consistent across PD-L1 subgroups (HR 0.28 in TPS 1 to 49%; HR 0.47 in TPS at least 50%) and histology subgroups. OS data were not mature at a median follow-up of 10.5 months (HR, 0.55; 95% CI, 0.36-0.85).

Grade 3 or higher treatment-emergent (AEs) occurred in 55.3% of patients in the combination arm versus 31.4% with pembrolizumab alone. The dominant TROP2 ADC-associated signals were neutropenia (17.3% grade 3/4), anemia (9.1%), and stomatitis (5.3%). Discontinuation rates were low at 3.8% to 5.3%. Whether a toxicity increment of this magnitude is an acceptable trade-off for a population currently receiving pembrolizumab monotherapy, one of the better-tolerated regimens in oncology, will be an important discussion as these data are reviewed. The trial was conducted entirely in China, and OS maturity will be required before practice implications for Western patients can be assessed.

Krascendo-170: Divarasib Plus Pembrolizumab in First-Line KRAS G12C NSCLC

Krascendo-170 reports early efficacy data from the PD-L1–positive cohort of a phase 1b/2 combination study. In 59 patients with untreated KRAS G12C-mutated NSCLC and TPS at least 1%, treated with divarasib 400 mg once daily plus pembrolizumab, the confirmed ORR was 73% (95% CI, 60-84), no patient had progressive disease as their best response, and the median PFS was 19.3 months (95% CI, 12.4 to not estimable) at a median follow-up of 12.2 months. In the PD-L1–negative cohort (23 patients, median follow-up 3.4 months), the unconfirmed ORR was 70%. These figures compare favorably to the 34% to 37% ORRs reported with sotorasib and adagrasib monotherapy in previously treated patients, although direct comparisons across trials are confounded by line of therapy, patient selection, and follow-up differences.

Grade 3 or higher treatment-related (AEs) occurred in 65% of patients. The hepatotoxicity signal is notable: Alanine aminotransferase elevation grade 3/4 in 20% and aspartate aminotransferase elevation in 18%, consistent with known KRAS inhibitor class effects but amplified in the combination setting. Treatment discontinuation was required in 25% of patients. These findings will need to be weighed against efficacy as the program advances. The randomized phase 3 Krascendo-2 trial (NCT06793215), testing divarasib plus pembrolizumab versus pembrolizumab plus chemotherapy in first-line KRAS G12C-mutated NSCLC, is currently enrolling and will provide the comparative efficacy and safety data necessary for regulatory evaluation.

TRIPLEX: Thoracic Radiotherapy Plus Chemoimmunotherapy in Extensive-Stage SCLC

TRIPLEX tests whether concurrent thoracic radiotherapy can improve outcomes when added to first-line chemoimmunotherapy in extensive-stage small cell lung cancer (SCLC). The trial, led by the Gronberg group in Norway, randomizes patients to concurrent thoracic radiotherapy plus platinum/etoposide and durvalumab versus chemotherapy plus durvalumab, building on the CASPIAN platform. The biological rationale includes radiation-induced immunogenic cell death and potential enhancement of immune checkpoint blockade through microenvironmental remodeling. Full results are embargoed.

Early-Phase Signals Worth Tracking

The developmental therapeutics sessions present several abstracts with potential implications for future lung cancer management. Two KRAS G12D inhibitor programs will report first-in-human data in NSCLC. KRAS G12D occurs in approximately 4% of NSCLCs and is the most prevalent KRAS mutation across all solid tumors. Unlike KRAS G12C, G12D lacks the reactive cysteine that enabled covalent inhibition with sotorasib and adagrasib, and it has been substantially more difficult to drug. Non-covalent and macrocyclic inhibitor strategies have now entered clinical testing, and these presentations will be the first public disclosure of human safety and preliminary efficacy data in lung cancer from two independent programs.

A phase 1b trial led by Stephen Liu, MD, at Georgetown University, evaluates the addition of lutetium-177 dotatate to standard first-line chemoimmunotherapy in extensive-stage SCLC. SCLC is a neuroendocrine cancer with somatostatin receptor 2 expression in 40% to 70% of tumors. NETTER-1 established proof-of-principle for SSTR2-directed radioligand therapy in gastroenteropancreatic neuroendocrine tumors (PFS HR 0.18). If SSTR2 expression in SCLC predicts response analogously, 68Ga-DOTATATE PET could serve as a patient selection tool, enabling the first biomarker-directed treatment strategy for this disease. A positive phase 1b signal would support development of a randomized study.

BH-30643, presented by Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, is a macrocyclic non-covalent EGFR inhibitor designed to retain activity across classical EGFR mutations, exon 20 insertions (a heterogeneous group of over 100 distinct variants), and the C797S tertiary resistance mutation that emerges after osimertinib therapy and for which no approved treatment currently exists. First-in-human safety and early efficacy data, including any CNS activity signals and responses in exon 20-inserted tumors, will be the primary results to evaluate.

Two further abstracts address early cellular immunotherapy approaches in lung cancer. NT-175 targets the TP53 R175H hotspot mutation using off-the-shelf pre-manufactured neoantigen T cells matched to common human leukocyte antigen (HLA) types, entering NSCLC for the first time. TP53 R175H is a shared public neoantigen present in approximately 10% of solid tumors across histologies, meaning a single manufactured product could be applied to multiple HLA-matched patients without individualized production. IMA401 uses a T-cell engager receptor bispecific antibody that bridges HLA-A*02:01/MAGE-A4/8 peptide complexes on tumor cells to CD3 on T cells, directing T-cell cytotoxicity toward intracellular oncoproteins presented via MHC class I. MAGE-A4/8 are expressed in 20% to 30% of squamous NSCLC, a histology with limited targeted therapy options. Both programs are at the first-in-human stage.

A Note on AI Decision Support in EGFR-Mutant NSCLC

Among the poster presentations, a study from investigators at Sylvester and collaborating institutions evaluates the performance of multiple artificial intelligence (AI) systems, including general-purpose large language models and guideline-constrained clinical platforms, against a panel of thoracic oncology experts across 12 EGFR-mutant metastatic NSCLC clinical vignettes spanning first- and second-line decision points. All systems showed at least moderate concordance with expert judgment in the first-line setting, where treatment recommendations are well-codified by guidelines. Performance deteriorated substantially in second-line scenarios, where evidence for post-osimertinib strategies remains limited. One system with strong first-line concordance showed near-inverse correlation with expert recommendations in second-line cases. Guideline-constrained platforms outperformed unconstrained large language models in first-line alignment. The results suggest that AI decision support tools are most reliable in clinical contexts where expert consensus is strongest and perform poorly in precisely the settings where clinicians most often seek external guidance.

ASCO 2026 and Beyond

The 2026 thoracic oncology program at ASCO covers a wide range of stages, molecular subtypes, and therapeutic mechanisms. The plenary presentations address two distinct and important questions: whether adjuvant targeted therapy can be extended to RET fusion-positive NSCLC, and whether a bispecific antibody combining PD-1 and VEGF blockade can improve on pembrolizumab plus chemotherapy in first-line squamous disease. Among the released abstracts, ALCHEMIST provides a definitive negative for post-surgical adjuvant immunotherapy in unselected EGFR/ALK-wild-type NSCLC and raises important questions about the role of immunotherapy timing. CROWN offers 7-year follow-up confirming durable disease control with lorlatinib in ALK-positive NSCLC. OptiTROP-Lung05 and Krascendo-170 report early-phase efficacy signals for ADC plus immunotherapy and KRAS G12C inhibitor plus immunotherapy combinations, respectively, with toxicity profiles that will require careful evaluation. TRITON presents an interim activity analysis in a biomarker-selected population with limited treatment options, with primary end points pending. The early-phase program addresses several of the most significant unmet needs in thoracic oncology, including KRAS G12D inhibition, radioligand therapy in SCLC, and cellular immunotherapy approaches in lung cancer.

Quick Reference: ASCO 2026 Lung Cancer Program at a Glance

Plenary sessions in bold red. Early-phase 1 developmental therapeutics in blue. LBA abstracts embargoed until day of presentation. Abstract numbers and presenters as of May 21, 2026.

Session / Trial	Presenter	Subtype / Setting	Type	Why You Should Be There
LIBRETTO-432 [PLENARY]	Jonathan W. Goldman, MD, UCLA	RET+ Resected NSCLC	Phase 3 LBA3	Full EFS data; could define adjuvant SOC for RET+ NSCLC. Watch the HR vs ADAURA/ALINA benchmarks. Embargoed until June 1.
HARMONi-6 [PLENARY]	Shun Lu, MD, Shanghai Chest Hospital	Sq-NSCLC, 1L	Phase 3 LBA4	OS data for ivonescimab vs PD-1 inhibitor + chemo; could displace pembrolizumab + chemo as 1L standard. Embargoed until June 1.
ALCHEMIST (EA5142)	Jamie Chaft, MD, MSK/ ECOG-ACRIN	Resected NSCLC (EGFR/ALK WT)	Phase 3 #8000	Negative for DFS (HR, 0.97) and PD-L1–high subset. Confirms timing of IO matters; OS not formally tested.
REVOL858R	Naoki Haratake, MD,Kyushu University/WJOG	EGFR L858R, 1L	Phase 3 LBA8518	Erlotinib + ramucirumab vs osimertinib; first L858R-specific sequencing trial. Embargoed until day of presentation.
CROWN 7yr	Tony Mok, MD, CUHK Hong Kong	ALK+ Advanced NSCLC	Phase 3 Update #8502	7-yr PFS rate 55% vs 3%; median PFS not reached. Pts event-free at 24 months have 79% probability of PFS at yr 7.
TRITON	Ferdinandos Skoulidis, MD, PhD, MD Anderson	STK11/KEAP1/KRAS NSCLC	Phase 2b IA #8515	Early ORR signal (39% vs 35%); durable responses with T+D+CT. PFS blinded; OS primary end point pending.
OptiTROP-Lung05	Caicun Zhou, MD,Shanghai East Hospital	PD-L1 ≥ 1% Advanced NSCLC	Phase 3 #8506	PFS HR 0.35 vs pembrolizumab alone; ORR 70% vs 42%. Grade ≥ 3 TEAEs 55% vs 31%. China-only; OS immature.
Krascendo-170	Ferdinandos Skoulidis, MD, PhD, MD Anderson	KRAS G12C NSCLC	Phase 1b/2 #8510	73% ORR, median PFS 19.3 months in PD-L1+ cohort. Grade 3/4 TRAEs 65%. Shapes Krascendo-2 phase 3 design.
TRIPLEX (ES-SCLC)	Aslaug Helland, MD, Oslo University Hospital	Extensive-Stage SCLC	Phase 3 LBA8005	Concurrent TRT + chemo + durvalumab vs chemo + durvalumab. Embargoed until day of presentation.
NT-175 (DT#2506)	Rishi Surana, MD, PhD, Dana-Farber	TP53 R175H Solid Tumors / NSCLC	Phase 1	Off-the-shelf neoantigen T-cell therapy targeting TP53 R175H; first-in-NSCLC.
IMA401 (DT#2507)	Martin Wermke, MD, Univ. Hospital Dresden	MAGE-A4/8+ NSCLC	First-in-human (FIH)	TCER bispecific targeting MAGE-A4/8 via MHC-I; off-the-shelf platform for sq-NSCLC.
KRAS G12D (DT#3006/7)	Zhengbo Song/Yiyi Yu	KRAS G12D NSCLC	Phase 1/2	First human G12D inhibitor data in lung cancer; largest undrugged oncogenic driver in solid tumors.
177Lu-DOTA-TATE (DT#3010)	Stephen Liu, MD, Georgetown	ES-SCLC (SSTR2+)	Phase 1b	Radioligand theranostic in SCLC; 68Ga-DOTATATE PET as selection tool for SSTR2+ patients.
BH-30643 (DT#3014)	Xiuning Le, MD, PhD, MD Anderson	EGFR Exon 20+ / C797S	FIH	Macrocyclic non-covalent EGFR inhibitor targeting exon 20 insertions, C797S, and classical mutations.
AI in EGFR NSCLC (Poster)	Chinmay Jani et al., Sylvester/Multi-institutional	EGFR-Mutant Metastatic NSCLC	Poster	AI concordance with experts in 1L EGFR NSCLC but not in 2L post-osimertinib; implications for clinical use.

References

1. Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC (ADAURA). N Engl J Med. 2023;389(2):137-147. doi:10.1056/NEJMoa23045942. 
2. Wu YL, Dziadziuszko R, Ahn JS, et al. Adjuvant alectinib in ALK-positive NSCLC (ALINA). N Engl J Med. 2024;390(14):1265-1276. doi:10.1056/NEJMoa2310532
3. Zhou C, Soloman B, Loong HH, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC. N Engl J Med. 2023;389:1839-1850. doi:10.1056/NEJMoa2309457
4. Eli Lilly and Company. Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer. Published February 16, 2026. Accessed May 2026. Data to be presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL.
5. Chen Z, Yang F, Jiang Z, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial. Lancet. 2025;406(10515):2078-2088. doi:10.1016/S0140-6736(25)01848-3
6. Forde PM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC (CheckMate 816): overall survival. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL. Abstract LBA8000.
7. Solomon BJ, Liu G, Felip E, et al. Lorlatinib vs crizotinib in advanced ALK-positive NSCLC (CROWN): 5-year results. J Clin Oncol. 2024;42(29):3400-3409. doi:10.1200/JCO.24.00581
8. Mok T, et al. Lorlatinib long-term outcomes in ALK-positive NSCLC (CROWN): 7-year update. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL. Abstract 8502.
9. Chaft J, et al. ALCHEMIST EA5142 trial results. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL. Abstract 8000.
10. Zhou C, et al. Sacituzumab tirumotecan in NSCLC (OptiTROP-Lung05). Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL. Abstract 8506.
11. Skoulidis F, et al. Divarasib in KRAS G12C–mutated NSCLC (Krascendo-170). Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL. Abstract 8510.
12. Skoulidis F, et al. Adagrasib-based combinations in KRAS G12C NSCLC (TRITON). Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL. Abstract 8515.
13. Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;20(12):1655-1669. doi:10.1016/S1470-2045(19)30634-5
14. Peters S, Chul Cho B, Luft AV, et al. Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic NSCLC: Five-year overall survival outcomes from the phase 3 POSEIDON trial. J Thorac Oncol. 2025;20(1):76-93. doi:10.1016/j.jtho.2024.09.1381
15. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN). Lancet. 2019;394(10212):1929-1939. doi:10.1016/S0140-6736(19)32222-6
16. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of lutetium-177–dotatate for midgut neuroendocrine tumors (NETTER-1). N Engl J Med. 2017;376(2):125-135. doi:10.1056/NEJMoa1607427
17. Jani C, et al. Artificial intelligence in EGFR-mutant NSCLC. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL. Abstract pending.